While heart disease, diabetes and prediabetes are the most common health concerns related to obesity, many other conditions ...

While this coincides with an uptick in GLP-1 drug use, some experts told Newsweek they don't think they are having a major ...

For decades, common wisdom and public health messaging have assumed that people in highly developed nations, like the United States, are relatively sedentary and burn far fewer daily calories than ...

Novo Nordisk goes "on the offensive" following Trump deal that also included rival Eli Lilly, putting an exclamation point on ...

Obesity among adults continues to be a major public health issue in the United States and other economically developed countries, according to the Centers for Disease Control and Prevention (CDC) and ...

The potential disadvantages of drugs increasingly used by patients to achieve greater weight loss are often not highlighted ...

Roughly 1 in 3 adults has metabolic dysfunction–associated steatotic liver disease, or MASLD. A doctor outlines how to detect and slow the condition early.

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Obesity severity is incrementally associated with a broad range of cardiometabolic and renal disease burden, as discovered by ...

Hypothalamic obesity (HyOb) is a type of obesity caused by damage to the brain’s hunger-regulating function. While there’s no cure, proper treatment can help improve your daily life and prevent ...